Nalgezin tablets p/o 275mg №10×1

Name:
Nalgezin tab., p / capt. vol., 275 mg in a blister. in pack. No. 10×1
Description:
Film-coated tablets, blue, oval, biconvex. The main active ingredient Naproxen Release form Tablets Dosage 275 mg Special instructions Use with caution in diseases of the liver and kidneys, diseases of the gastrointestinal tract in history, in the presence of dyspeptic symptoms, in arterial hypertension, heart failure, immediately after major surgical interventions. In the process of treatment, systematic monitoring of the function of the liver and kidneys, the picture of peripheral blood is necessary. If it is necessary to determine the concentration of 17-ketosteroids, naproxen should be discontinued 48 hours before the study. Pharmacological action of NSAIDs, a derivative of naphthylpropionic acid. It has anti-inflammatory, analgesic and antipyretic effects. The mechanism of action is associated with inhibition of the COX enzyme, which leads to inhibition of the synthesis of prostaglandins from arachidonic acid. Suppresses platelet aggregation. Reduces pain syndrome, incl. joint pain at rest and during movement, morning stiffness and swelling of the joints, contributes to an increase in range of motion. The anti-inflammatory effect occurs by the end of the 1st week of treatment. Pharmacokinetics After oral administration, naproxen is rapidly absorbed from the gastrointestinal tract. Cmax in plasma is reached after 1-4 hours. Food slows down the rate of absorption, but does not reduce the degree of absorption. Naproxen is well absorbed when administered rectally, but absorption is slower than when taken orally. At therapeutic concentrations, naproxen is more than 99% bound to plasma proteins. Plasma concentrations of naproxen increase proportionately at doses up to 500 mg, at higher doses there is an increase in clearance due to saturation of plasma proteins. Naproxen diffuses into the synovial fluid. T1 / 2 is about 13 hours. Approximately 95% of the dose is excreted in the urine as unchanged substance and 6-O-desmethylnaproxen and its conjugates. Less than 5% is administered with feces. Indications for use Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome during exacerbation of gout; pain in the spine, neuralgia, myalgia, traumatic inflammation of the soft tissues and the musculoskeletal system. Method of application and doses The method of application and the dosing regimen of a particular drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed. Set individually, taking into account the severity of the course of the disease. Inside adults – 0.5-1 g / day in 2 divided doses. The daily dose for maintenance treatment is 500 mg. The maximum daily dose is 1.75 g. Use during pregnancy and lactation Use with caution during pregnancy (especially in the I and III trimesters) and during lactation. Naproxen crosses the placental barrier and is excreted in breast milk in small amounts. Precautions Take special precautions when taking: if you have or have had gastrointestinal diseases in the past, your doctor should carefully monitor your condition; special care should be taken in ulcerative colitis and Crohn’s disease, tk. these conditions may recur or worsen. Serious gastrointestinal side effects may occur without any previous illness; possible bleeding and intestinal perforations (holes in the intestinal wall); if you have impaired kidney or liver function; if you have heart failure; if you are being treated for epilepsy or have a very rare disorder of blood pigment metabolism (porphyria); with extensive fresh wounds and at least 48 hours before a planned major operation; at an increased risk of allergic reactions (chronic hay fever, nasal polyps or obstructive pulmonary disease); if you are allergic to other NSAIDs; if you suffer from blood disorders. Taking NSAIDs may be associated with a slight increase in cardiovascular risks (myocardial infarction or stroke). Any risk is more likely with high doses and long-term treatment. Do not exceed the recommended dose or duration of treatment (3 days for fever relief or 10 days for pain relief). If you have heart problems, have had a stroke, or think you may be at risk for these conditions (for example, if you have high blood pressure, diabetes, high cholesterol, or are a smoker), you should consult your doctor. Very rarely, serious skin reactions (some of which can be fatal), skin inflammation with scaling, toxic epidermal necrolysis (severe, extensive skin blistering rash with redness and scaling), and Stevens-Johnson syndrome (severe blistering rash in the mouth, eye and genital areas) associated with the use of NSAIDs. Patients appear to be most at risk for these reactions early in therapy; treatment should be discontinued at the first appearance of such reactions (skin rash, skin tissue changes, other signs of hypersensitivity). As with all drugs taken by the elderly, naproxen sodium should be used at the lowest effective dose. The concomitant use of Nalgesin® and alcohol (three or more glasses daily regularly) may increase the risk of stomach bleeding. If you already have hives, swelling of the face, an asthma attack, or even shock after taking other medicines to relieve pain or reduce fever, do not take Nalgesin® without consulting a doctor. Nalgezin® is not recommended for children under 12 years of age. Nalgezin® may make it difficult to get pregnant. The effect disappears after treatment is stopped. Interaction with other drugs When used simultaneously with antacids containing magnesium and aluminum, sodium bicarbonate, the absorption of naproxen decreases. With simultaneous use with indirect anticoagulants, cases of a slight increase in the action of anticoagulants are described. With simultaneous use with amoxicillin, a case of the development of nephrotic syndrome is described; with acetylsalicylic acid – a decrease in the concentration of naproxen in the blood plasma is possible. With simultaneous use, it is possible to change the pharmacokinetic parameters of diazepam; with caffeine – the effect of naproxen is enhanced; with lithium carbonate – it is possible to increase the concentration of lithium in the blood plasma; with methotrexate – it is possible to increase the toxicity of methotrexate. There are reports of the development of myoclonus with simultaneous use with morphine. With simultaneous use with prednisolone, a significant increase in the concentration of prednisolone in the blood plasma is possible; with probenecid – a decrease in the concentration of naproxen in the blood plasma; with salicylamide – the effect of salicylamide is enhanced. With simultaneous use with furosemide, a decrease in the diuretic effect of furosemide is possible. Contraindications Erosive and ulcerative lesions of the gastrointestinal tract in the acute phase, “aspirin triad”, hematopoietic disorders, severe renal dysfunction (CC less than 20 ml / min), severe liver dysfunction, children under 12 years of age; hypersensitivity to naproxen and other NSAIDs. Shell composition: Opadry YS-1-4215 (titanium dioxide (E171), macrogol, indigo carmine dye (E132), hypromellose). 10 pieces. – blisters (1) – packs of cardboard. 10 pieces. – blisters (2) – packs of cardboard. Overdose Side effect From the digestive system: nausea, vomiting, discomfort in the epigastrium; rarely – erosive and ulcerative lesions of the gastrointestinal tract, bleeding and perforation of the gastrointestinal tract, impaired liver function. From the side of the central nervous system and peripheral nervous system: headache, drowsiness, slowing down the speed of psychomotor reactions; rarely – hearing impairment. From the hemopoietic system: rarely – thrombocytopenia, granulocytopenia, aplastic anemia, hemolytic anemia. From the respiratory system: rarely – eosinophilic pneumonia. From the urinary system: rarely – impaired renal function. Allergic reactions: skin rash, urticaria, angioedema. When applied rectally: the appearance of mucous secretions mixed with blood, painful defecation. Storage conditionsStore at a temperature not exceeding 30°C. Store in original packaging to protect from light. Keep out of the reach of children. Shelf life 5 years. Do not use the medicine after the expiry date which is stated on the package. The expiry date is the last day of the month. Do not dispose of the drug in the water supply or sewerage. Ask your pharmacist how to dispose of drugs you no longer need. These measures will help protect the environment. Buy Nalgezin tablets p/o 275mg №10×1 Price for Nalgezin tablets p/o 275mg №10×1